Abstract:Bivalent ligands--compounds incorporating two receptor-interacting moieties linked by a flexible chain--often exhibit profoundly enhanced binding affinity compared with their monovalent components, implying concurrent binding to multiple sites on the target protein. It is generally assumed that neurotransmitter sodium symporter (NSS) proteins, such as the dopamine transporter (DAT), contain a single domain responsible for recognition of substrate molecules. In this report, we show that molecules possessing two substrate-like phenylalkylamine moieties linked by a progressively longer aliphatic spacer act as progressively more potent DAT inhibitors (rather than substrates). One compound bearing two dopamine (DA)-like pharmacophoric 'heads' separated by an 8-carbon linker achieved an 82-fold gain in inhibition of [(3)H] 2beta-carbomethoxy-3beta-(4-fluorophenyl)-tropane (CFT) binding compared with DA itself; bivalent compounds with a 6-carbon linker and heterologous combinations of DA-, amphetamine- and beta-phenethylamine-like heads all resulted in considerable and comparable gains in DAT affinity. A series of short-chain bivalent-like compounds with a single N-linkage was also identified, the most potent of which displayed a 74-fold gain in binding affinity. Computational modelling of the DAT protein and docking of the two most potent bivalent (-like) ligands suggested simultaneous occupancy of two discrete substrate-binding domains. Assays with the DAT mutants W84L and D313N--previously employed by our laboratory to probe conformation-specific binding of different structural classes of DAT inhibitors--indicated a bias of the bivalent ligands for inward-facing transporters. Our results strongly indicate the existence of multiple DAT substrate-interaction sites, implying that it is possible to design novel types of DAT inhibitors based upon the 'multivalent ligand' strategy.

Structure of the human dopamine transporter and mechanisms of inhibition

Structure of the human dopamine transporter in complex with cocaine

Dopamine reuptake and inhibitory mechanisms in human dopamine transporter

Cryo-EM structure of the dopamine transporter with a novel atypical non-competitive inhibitor bound to the orthosteric site

Substrate-induced Conformational Dynamics of the Dopamine Transporter

Structure-Based Discovery of a Novel Allosteric Inhibitor against Human Dopamine Transporter

A direct interaction of cholesterol with the dopamine transporter prevents its out-to-inward transition

Expression and regulation of the human dopamine transporter in a neuronal cell line (vol 59, pg 66, 1998)

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

A Juxtamembrane Mutation in the N Terminus of the Dopamine Transporter Induces Preference for an Inward-Facing Conformation

Dopaminergic Pharmacology Revealed by Structures of Human Dopamine D3 Receptor-G I Complexes

Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities

Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse

Development of Peptidic Dopamine Transporter Inhibitors Via Aromatic Modification-Mediated Conformational Restriction.

Structural mechanisms for VMAT2 inhibition by tetrabenazine

Characterization of Novel Pyrovalerone Analogs as Potential Dopamine Transporter Irreversible Ligands

Site-Directed Mutations Near Transmembrane Domain 1 Alter Conformation and Function of Norepinephrine and Dopamine Transporters

Structural insights into the human D1 and D2 dopamine receptor signaling complexes

Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, at mammalian cells expressing the dopamine transporter

Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter